Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGNYZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ligand Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ligand Pharma's regulatory disclosures and financial reporting.
Ligand Pharmaceuticals insider selling notice: A Form 144 reports a planned sale of 467 shares of Ligand common stock through UBS Financial Services Inc., with an aggregate market value of 89,748.06. The shares are listed on Nasdaq, and 19,681,720 shares were outstanding at the time referenced.
The shares to be sold are common stock acquired on 04/24/2024 from the issuer in various transactions, totaling 467 shares. The filing also notes that John Kozarich has sold 467 common shares in each of three transactions over the past three months, with gross proceeds of 91,456.91, 89,219.00, and 88,532.51.